ClinicalTrials.gg
CompletedNCT04494659Updated Sep 29, 2020

A Drug-drug Interaction Trial to Evaluate the Pharmacokinetics Effect of Rifampicin on Famitinib

A Phase 1 interventional study of Famitinib capsule and Rifampicin capsule in Healthy Adult Subjects, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-29.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The primary objective of the study was to assess the effect of repeated oral doses of Rifampicin on the pharmacokinetic profile of a single dose of Famitinib.

The secondary objective of the study was to assess the safety of Famitinib given alone versus Famitinib co-administered with Rifampicin.

02

Conditions studied

  • Healthy Adult Subjects
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects aged 18 to 50 years old at the date of signing the ;
  2. Male body weight ≥ 50kg, (BMI) within the range of 19 \~ 28 kg/m2 (including 19 and 28) (BMI= weight (kg)/height 2 (m2));
  3. Subjects have no childbirth plans and agree to take effective measures within 3 months of the last medication;
  4. The subject can communicate well with the researcher, understand and comply with the requirements of the study, understand and sign the informed consent.

Exclusion criteria

Exclusion Criteria:

  1. History of or currently suffering from any serious clinical diseases such as diseases in circulatory system, endocrine system, nervous system, digestive system, respiratory system, genitourinary system, hematology, immunology, psychiatry, and metabolic abnormalities, or any other diseases may interfere with the test results;
  2. Any surgery within 6 months before screening, or plan to perform surgery during the study period, or who have previously undergone any surgery that affects gastrointestinal absorption (including gastrectomy, bowel resection, gastric reduction surgery, etc.)
  3. Blood donation or massive blood loss (≥200 mL), or received blood transfusion, or used blood products within 3 months before screening;
  4. History of allergy to drugs, food or other substances;
  5. Frequent use of sedatives, sleeping pills or other addictive drugs; History of drug abuse within 1 year prior to screening; Positive for urine drug abuse screening test;
  6. Participated in any clinical trial and took the study drug within 3 months prior to the first administration;
  7. Used any prescription drug or herbal tonic within 1 month before the first administration; Have used any over-the-counter (OTC) medicines, food supplements (including vitamins, calcium tablets, etc.) within 2 weeks prior to the first administration;
  8. Those who had smoked more than 5 cigarettes per day in the previous 3 months before screening and could not stop using any tobacco products during the study period; Nicotinic test positive;
  9. Frequent drinkers in the previous 6 months before screening, i.e., those who drink more than 14 units of alcohol per week (1 unit = 285 mL beer, or 25 mL spirits, or 100 mL wine) and cannot stop using any alcoholic products during the study period; alcohol test positive;
  10. Abnormal vital signs, physical examination, 12-lead , abdominal B-ultrasound, chest radiograph, routine blood test, biochemical test, routine urine test and blood coagulation test with clinical significance;
  11. surface antigen positive, antibody positive, syphilis antibody positive, antibody positive;
  12. Subjects have taken and do not agree to stop using any drink or food containing methylxanthine, such as coffee, tea, cola, chocolate, etc. from 48 hours before the first administration until end of the study;, subjects have taken and do not agree to discontinue any beverage or food containing grapefruit from 7 days prior to initial administration until end of the study; Those who have special requirements on diet and cannot follow a uniform diet;
  13. Subjects who are considered to have other factors that are not appropriate to participate in this study by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Single arm

    single dose of Famitinib on Day 1, and co-administered with Rifampicin on Day 16

    Drug: Famitinib capsule · Drug: Rifampicin capsule

Interventions

  • single dose and co-administrated with Rifampicin capsule

    Also known as: SHR1020

  • repeated doses of Rifampicin capsule

    Also known as: Rifampicin

06

What researchers measure

Primary outcomes

  1. Cmax of Famitinib

    Pharmacokinetics parameters of Famitinib

    Time frame: Day 1 to Day 24

  2. AUC0-t of Famitinib

    Pharmacokinetics parameters of Famitinib

    Time frame: Day 1 to Day 24

  3. AUCinf of Famitinib

    Pharmacokinetics parameters of Famitinib

    Time frame: Day 1 to Day 24

Secondary outcomes

  1. Tmax of Famitinib

    Pharmacokinetics parameters of Famitinib

    Time frame: Day 1 to Day 24

  2. T1/2 of Famitinib

    Pharmacokinetics parameters of Famitinib

    Time frame: Day 1 to Day 24

  3. CL/F of Famitinib

    Pharmacokinetics parameters of Famitinib

    Time frame: Day 1 to Day 24

  4. Vz/F of Famitinib

    Pharmacokinetics parameters of Famitinib

    Time frame: Day 1 to Day 24

  5. incidence of adverse events/serious adverse events

    safety evaluation based on NCI-CTC AE 5.0

    Time frame: from ICF signing date to approximate Day 31

07

Study locations

1 site
  • Affiliated Hospital of Qingdao University
    Qingdao, Shandong 266055, China
08

References and documents

Publications

  • Li T, Li X, Jiang X, Wang C, Sun F, Liu Y, Lin P, Shi P, Fu Y, Gao X, Zhang Y, Cao Y. The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects. Cancer Chemother Pharmacol. 2022 Nov;90(5):409-415. doi: 10.1007/s00280-022-04474-8. Epub 2022 Sep 15. PubMed 36107220 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Aug 2020, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2020
First posted
Jul 31, 2020
StartActual
Jul 20, 2020
Primary completionActual
Aug 13, 2020
CompletionActual
Aug 31, 2020
Last update
Sep 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04494659
Responsible party
Sponsor
First posted
Jul 31, 2020
Start date
Jul 20, 2020
Primary completion
Aug 13, 2020
Completion
Aug 31, 2020
Last update
Sep 29, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Famitinib · Rifampin

Start the discussion